Skip to content

Addiction research published in 2023

Page 4 of 6: studies 61 to 80 of 114, newest first. Back to the addiction overview

Studies

Modulation of Gut Microbiome in Ecstasy/MDMA-Induced Behavioral and Biochemical Impairment in Rats and Potential of Post-Treatment with Anacyclus pyrethrum L. Aqueous Extract to Mitigate Adverse Effects.

International Journal of Molecular Sciences May 22, 2023 Abdelmounaim Baslam, Abdelfatah Aitbaba, Asmae Lamrani Hanchi et al. 16 citations

The use of illicit substances continues to pose a substantial threat to global health, affecting millions of individuals annually. Evidence suggests the existence of a 'brain-gut axis' as the involving connection between the central nervous system and gut microbiome (GM). Dysbiosis of the GM has been associated with the pathogenesis of various chronic diseases, including metabolic, malignant,...

Psychometric Assessment of the Applied Mindfulness Process Scale (AMPS) Among a Sample of Women in Treatment for Substance Use Disorder

Mindfulness May 20, 2023 Shaddy K. Saba, David Scott Black 2 citations

Abstract Objectives The Applied Mindfulness Process Scale (AMPS) is a measure used to quantify the level at which individuals apply learned mindfulness skills during and after a mindfulness-based intervention (MBI). The AMPS was previously developed and validated among individuals with mindfulness experience and in good health. The utility of the AMPS among individuals receiving an MBI for a...

Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.

Cell May 11, 2023 Isha Singh, Anubha Seth, Christian B. Billesbølle et al. 97 citations

The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has unusual anti-depressant and substance-withdrawal effects, and stabilizes the inward-open conformation. Unfortunately, ibogaine's promiscuity...

Altered neural associations with cognitive and emotional functions in cannabis dependence.

Cerebral Cortex May 4, 2023 Xinying Wang, Hui Zhou, Yuzheng Hu

Negative emotional state has been found to correlate with poor cognitive performance in cannabis-dependent (CD) individuals, but not healthy controls (HCs). To examine the neural substrates underlying such unusual emotion-cognition coupling, we analyzed the behavioral and resting state fMRI data from the Human Connectome Project and found opposite brain-behavior associations in the CD and HC...

Long-term effects of THC exposure on reward learning and motivated behavior in adolescent and adult male rats.

Psychopharmacology May 2023 Briac Halbout, Collin Hutson, Leann Hua et al.

The endocannabinoid system makes critical contributions to reward processing, motivation, and behavioral control. Repeated exposure to THC or other cannabinoid drugs can cause persistent adaptions in the endocannabinoid system and associated neural circuitry. It remains unclear how such treatments affect the way rewards are processed and pursued. We examined if repeated THC exposure (5...

Ketamine Treatment for Alcohol Use Disorder: A Systematic Review.

Cureus May 1, 2023 Michael Kelson, Justin M Burnett, Amy Matthews et al. 32 citations

Alcohol use disorder (AUD) is a chronic, recurrent condition that demonstrates significant heterogeneity in treatment response to first-line agents. Ketamine may have a therapeutic role in substance use disorders; however, research on this topic is limited. The objective of this systematic review is to qualitatively synthesize the current evidence of ketamine treatment for alcohol use disorder...

The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review

Frontiers in Psychiatry April 27, 2023 Charlotte Goldfine, Jeremiah J. Tom, Dana D. Im et al. 30 citations

Introduction: Alcohol use disorder (AUD) is the most prevalent substance use disorder (SUD) globally. In 2019, AUD affected 14.5 million Americans and contributed to 95,000 deaths, with an annual cost exceeding 250 billion dollars. Current treatment options for AUD have moderate therapeutic effects and high relapse rates. Recent investigations have demonstrated the potential efficacy of...

Mini-review: The neurobiology of treating substance use disorders with classical psychedelics

Frontiers in Neuroscience April 17, 2023 Marvin M. Urban, Moritz R. Stingl, Marcus W. Meinhardt 47 citations

The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsible for their therapeutic effects have not yet been fully elucidated. While it is known that serotonergic hallucinogens induce changes in gene expression and neuroplasticity, particularly in prefrontal regions, theories on how specifically this...

Development of a mobile mindfulness smartphone app for post-traumatic stress disorder and alcohol use problems for veterans: Beta test results and study protocol for a pilot randomized controlled trial.

Contemporary Clinical Trials April 12, 2023 Jordan P Davis, Eric R Pedersen, Brian Borsari et al.

Background: Post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) are highly prevalent, and co-occurring among post-9/11 veterans. Mobile health (mHealth) applications, specifically those focused on mindfulness-based techniques, may be an effective avenue to intervene with veterans who cannot or will not seek care at traditional in-person settings. Thus, to address areas of...

Altered functional connectivity and oscillatory dynamics in polysubstance and cannabis only users during visuospatial processing.

Psychopharmacology April 2023 Lucas Weyrich, Yasra Arif, Mikki Schantell et al.

Cannabis use is often associated with the use of other psychoactive substances, which is subsequently linked to an increased risk for addiction. While there is a growing body of neuroimaging literature investigating the cognitive effect of long-term cannabis use, very little is known about the potential additive effects of cannabis polysubstance use. Fifty-six adults composed of 18...

Mindfulness-Oriented Recovery Enhancement remediates anhedonia in chronic opioid use by enhancing neurophysiological responses during savoring of natural rewards.

Psychological Medicine April 1, 2023 Eric L Garland, Spencer T Fix, Justin Hudak et al. 51 citations

Neuropsychopharmacologic effects of long-term opioid therapy (LTOT) in the context of chronic pain may result in subjective anhedonia coupled with decreased attention to natural rewards. Yet, there are no known efficacious treatments for anhedonia and reward deficits associated with chronic opioid use. Mindfulness-Oriented Recovery Enhancement (MORE), a novel behavioral intervention combining...

IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.

Pharmacological Research April 1, 2023 Deborah C. Mash 37 citations

Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a very long history of ethnobotanical use in low doses to combat fatigue, hunger and thirst and, in high doses as a sacrament in African ritual contexts. In the 1960's, American and European self-help groups provided public testimonials that a single...

The Varieties of Psychedelic Expertise in 1960s Canada: The Psychiatrists behind the Addiction Research Foundation's Study of LSD Therapy.

Canadian journal of health history = Revue canadienne d'histoire de la sante April 1, 2023 Andrew Jones 2 citations

In 1962, Ontario's Addiction Research Foundation launched the first double-blind randomized controlled trial of LSD therapy as a treatment for alcoholism. The study, which found that LSD was not effective, was heavily criticized by other therapists working with the drug. These critics argued that the Toronto researchers who carried out the study were biased against LSD and used an...

The effect of mindfulness on social media addiction among Chinese college students: A serial mediation model

Frontiers in Psychiatry March 23, 2023 H. Chang, Xiaolu Meng, Yaqi Li et al.

Introduction The COVID-19 pandemic has exacerbated social media addiction (SMA), making it urgent to find effective interventions for social media addiction. Evidence has shown that mindfulness might be an effective intervention for social media addiction. However, psychological mechanisms by which mindfulness reduce social media use remain unclear. Here, we further addressed this issue to...

Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism

Cells March 22, 2023 Kevin Domanegg, Wolfgang H. Sommer, Marcus W. Meinhardt 23 citations

Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved pharmacotherapies have demonstrated limited effectiveness over the last few decades in treating alcohol use disorders (AUD). New therapeutic approaches are therefore urgently needed. Historical and recent clinical trials using psychedelics in conjunction with psychotherapy demonstrated encouraging results in...

DOI: 10.3390/cells12060963 (opens in new tab) Addiction Metabotropic glutamate receptor Metabotropic receptor Pharmacology +1

The Acceptability and Feasibility of a Virtual Mantram Program for Patients with Posttraumatic Stress Disorder and Substance Use Disorders: Mixed Method results

Research Square March 20, 2023 Ahmed N. Hassan, Sean Ferkul, Zena Agabani et al. preprint

Abstract Background : There is a need for expanded options for therapeutic interventions for patients with posttraumatic stress disorder (PTSD) and substance use disorder (SUD). The study aimed to examine evidence for the feasibility, safety, and acceptability of a virtual Mantram Repetition Program for adults with PTSD and SUD. Methods : This project utilized mixed-method design (explanatory...

DOI: 10.21203/rs.3.rs-2605978/v1 (opens in new tab) Full text (opens in new tab) Mindfulness Psychological intervention Substance abuse Clinical psychology +3

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review

Journal of Psychoactive Drugs March 18, 2023 Raman Sharma, Rachel Batchelor, Jacqueline Sin 25 citations

Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders including substance use disorder (SUD). This review aimed to assess the effectiveness of psychedelic treatments for people with SUD and those falling below diagnostic thresholds (i.e. substance misuse). We systematically searched 11 databases, trial...

Deletion of Cryab increases the vulnerability of mice to the addiction-like effects of the cannabinoid JWH-018 via upregulation of striatal NF-κB expression

Frontiers in Pharmacology March 16, 2023 Leandro Val Sayson, Darlene Mae Ortiz, Hyun Jun Lee et al. 4 citations

Synthetic cannabinoids have exhibited unpredictable abuse liabilities, especially self-administration (SA) responses in normal rodent models, despite seemingly inducing addiction-like effects in humans. Thus, an efficient pre-clinical model must be developed to determine cannabinoid abuse potential in animals and describe the mechanism that may mediate cannabinoid sensitivity. The Cryab...

DOI: 10.3389/fphar.2023.1135929 (opens in new tab) Addiction Synaptic plasticity Conditioned place preference Neuroinflammation +11

Value Signals Guiding Choices for Cannabis Versus Non-Drug Rewards in Regular Cannabis Users

March 15, 2023 Will Lawn, Xuejun Hao, Anna B. Konova et al. preprint

Background: Despite the critical role of choice processes in substance use disorders, the neurobehavioral mechanisms guiding human decisions about drugs remain poorly understood. We adapted a neuroeconomic framework to characterize the neural encoding of subjective value (SV) for cannabis versus non-drug rewards (snacks) in near-daily cannabis users. We also assessed the impact of cannabis and...

MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case study

March 10, 2023 Mika Turkia 1 citation preprint

In February 2023, Australia became the first country in the world to allow psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD). This may have left interested clinicians looking for practical examples of the use of MDMA. In the 1950s and 1960s, psychedelics were successfully utilized in the treatment of alcoholism. This case study, the...